Book · Julian R. Sterling

The Life Science Real Estate Investor

Underwriting Lab and R&D Buildings: Biotech Tenant Credit, Tenant Improvements, Office-to-Lab Conversion, Development and the 2021 to 2026 Cycle

About the book

Cover of The Life Science Real Estate Investor

It is November 2026, and the associate on a real estate fund's acquisitions team opens a data room: a four-story lab building of 150,000 rentable square feet, three tenants, one empty suite, and a market where a large share of lab space still stands vacant. More than a third of the rent comes from a clinical-stage biotech with no product revenue and 22.5 months of cash left. The building cost more to build than most buyers will pay for it today.

The Life Science Real Estate Investor is a practitioner's guide to underwriting lab and R&D buildings: what makes life science space different, where its tenants' money comes from, what the 2021 to 2026 cycle did to rents, vacancy and values, how to test a building before any spreadsheet, how to read a lab lease and judge a tenant that lives on investors' money, and how to price tenant improvements and downtime. One fictional fund, Quaywright Life Science Fund I, is followed through the purchase of the Corlund Science Center, from the first look at the rent roll to the investment committee and the exit. Every figure of the case comes from one model.

Some of what the arithmetic shows: why a new lease with a face rent of $74.16 per RSF nets $62.60 once the months without rent, TI and commissions are paid; why a going-in yield of 6.56 percent becomes a levered return of 13.64 percent, and falls to 6.47 percent if the biotech fails and the exit yield rises; why converting a 1988 office building to lab yields 5.84 percent on cost and loses money; and why a new building needs a rent of $88.53 per RSF just to be worth what it costs.

The model is not described, it is supplied. A companion workbook rebuilds the case by live formula, with a Checks sheet and an exercise for every lever, and the checklists come as an editable document. The closing pages say where to find them.

What you will be able to do:

Sixteen chapters in three parts and four appendices: a guide to the workbook with ten exercises, eight life science real estate checklists, thirty-six interview and investment committee questions with model answers, and a glossary of sixty terms.

Written for acquisitions analysts and associates, asset and portfolio managers, lenders and credit analysts in lab and R&D real estate, brokers and appraisers moving into lab, developers' finance teams, and life science executives who sign leases. The case, its fund, buildings, tenants and figures are fictional teaching assumptions, not the terms of any real building, tenant or lender; real-world facts are dated as of 2026 and change. This book is for education only. It is not legal, tax, engineering or investment advice. Part of The Private Markets Career Guides.

How this book was made: written with the help of artificial intelligence tools, under the author's direction; every figure was computed by a model and every rule was checked against its source.

What is inside

Also by Julian R. Sterling

Related titles. The full list is on the author page.